The Translational and Analytical Chemistry Core (TACC) consists of a Chemistry Core Facility and a Nuclear Magnetic Resonance (NMR) Facility. The Chemistry Core began operations in July 2006 and was designated a CCSG developmental shared resource in July 2008. In 2012, the NMR Facility was moved from the Pharmacology &Analytical Facility to the TACC. The mission of the combined core is to assist researchers with the design, synthesis, and analysis of compounds for use in cancer research. The facility is a state-of-the-art organic chemistry lab, offering services ranging from drug design to pre-clinical drug development. The TACC offers two innovative services that other synthesis cores do not. The molecular modeling service allows design of ab inito new chemical agents. Additionally, the TACC offers small molecule X-ray crystallography. The Chemistry Core has experienced average yearly growth of 36% for design and synthesis services (Development, Modeling, and Custom Synthesis) and a decline of 7% for the analytical services (Mass Spec and X-ray). Over the last 5 years, the Chemistry Core has completed 69 projects and synthesized 144 compounds for 35 cancer center members, representing more than 11,200 hours of service. Major equipment for the Chemistry core includes Varian LC-940 HPLC systems, an Agilent Accurate-Mass TOF LC/MS and a Bruker SMART X2S Automated Bench Top X-ray system. The NMR facility is used primarily for structure determination of compounds developed in drug discovery, pharmacology, and diagnostic imaging laboratories. Other uses include macromolecular structure determination and metabolism studies. Usage of the NMR facility increased 147% over the past five years. Instrumentation consists of Bruker 300 MHz DPX, 500 MHz DRX and 600 MHz Avance NMR spectrometers. In the past five years researchers from thirty-two research groups have utilized the laboratory. Peer reviewed investigators account for 87% of utilization of chemistry services and 46% of utilization of the NMR Facility. For the coming grant cycle, TACC requests $232,209 (24%) support from the CCSG. The institution has provided $1,598,359 for purchase of TACC equipment. Publications cited using the TACC have appeared in J Clin Invest and J Natl Cancer Inst. Future plans include the proposed expansion of the facility to incorporate compound screening to provide for early stage hits and access to GMP capabilities to support clinical research studies. The NMR Facility will continue to support the drug discovery and imaging agent research at MD Anderson, and plans to expand into support of metabolomics research.

Public Health Relevance

The Translational and Analytical Chemistry Core provides the capability to synthesize compounds that otherwise would be difficult and costly to obtain through other sources. Novel compounds can also be designed and synthesized to order against a particular biological target. The NMR facility is used extensively for drug discovery and diagnostic imaging research at MD Anderson.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-39
Application #
8759768
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
$266,194
Indirect Cost
$99,893
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Shen, Hui; Shih, Juliann; Hollern, Daniel P et al. (2018) Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep 23:3392-3406
Boddu, Prajwal; Masarova, Lucia; Verstovsek, Srdan et al. (2018) Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97:109-121
Casasent, Anna K; Schalck, Aislyn; Gao, Ruli et al. (2018) Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing. Cell 172:205-217.e12
Noh, Hyangsoon; Zhao, Qingnan; Yan, Jun et al. (2018) Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett 433:176-185
Hutcheson, Katherine A; Barrow, Martha P; Plowman, Emily K et al. (2018) Expiratory muscle strength training for radiation-associated aspiration after head and neck cancer: A case series. Laryngoscope 128:1044-1051
Zhao, Jun; Xiao, Zhilan; Li, Tingting et al. (2018) Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. ACS Nano 12:9881-9893
Akhtari, Mani; Milgrom, Sarah A; Pinnix, Chelsea C et al. (2018) Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood 131:84-94
Barua, Souptik; Solis, Luisa; Parra, Edwin Roger et al. (2018) A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms. Cancer Inform 17:1176935118782880
Ma, Junsheng; Chan, Wenyaw; Tilley, Barbara C (2018) Continuous time Markov chain approaches for analyzing transtheoretical models of health behavioral change: A case study and comparison of model estimations. Stat Methods Med Res 27:593-607
Bayraktar, Recep; Ivan, Cristina; Bayraktar, Emine et al. (2018) Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clin Cancer Res 24:4225-4241

Showing the most recent 10 out of 12418 publications